

M Angela Cenci Nilsson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8242104/m-angela-cenci-nilsson-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107
papers

8,277
citations

47
h-index

90
g-index

113
ext. papers

9,148
ext. citations

6.6
avg, IF

6.18
L-index

#	Paper	IF	Citations
107	Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.. <i>Neuropharmacology</i> , 2022 , 210, 109027	5.5	4
106	Non-Apoptotic Caspase-3 Activation Mediates Early Synaptic Dysfunction of Indirect Pathway Neurons in the Parkinsonian Striatum. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5470	6.3	0
105	Toxin-Based Rodent Models of Parkinson's Disease. <i>NeuroMethods</i> , 2021 , 3-19	0.4	
104	Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism. <i>Neurobiology of Disease</i> , 2021 , 157, 105429	7.5	1
103	The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications. <i>Progress in Brain Research</i> , 2020 , 252, 131-168	2.9	10
102	Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini. <i>Movement Disorders</i> , 2020 , 35, 901	7	
101	Animal models for preclinical Parkinson's research: An update and critical appraisal. <i>Progress in Brain Research</i> , 2020 , 252, 27-59	2.9	10
100	D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease. <i>Journal of Clinical Investigation</i> , 2020 , 130, 1168-1184	15.9	17
99	Dyskinesia matters. <i>Movement Disorders</i> , 2020 , 35, 392-396	7	24
98	Cortico-Striatal Oscillations Are Correlated to Motor Activity Levels in Both Physiological and Parkinsonian Conditions. <i>Frontiers in Systems Neuroscience</i> , 2020 , 14, 56	3.5	3
97	Seeding of protein aggregation causes cognitive impairment in rat model of cortical synucleinopathy. <i>Movement Disorders</i> , 2019 , 34, 1699-1710	7	18
96	Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease. <i>Neurotherapeutics</i> , 2019 , 16, 465-479	6.4	34
95	Significance and Translational Value of High-Frequency Cortico-Basal Ganglia Oscillations in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 183-196	5.3	7
94	Animal models of l-dopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 889-899		47
93	mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia. <i>Current Opinion in Pharmacology</i> , 2018 , 38, 81-89	5.1	36
92	Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 2	7.3	34
91	On the neuronal circuitry mediating L-DOPA-induced dyskinesia. <i>Journal of Neural Transmission</i> , 2018 , 125, 1157-1169	4.3	26

90	Posters presentation selected for the blue ribbon session at the annual meeting of the Parkinson's disease and movement disorders society (Hong Kong, October, 2018).. <i>Movement Disorders</i> , 2018 , 33, 1977-1991	7	
89	Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease. <i>Neurobiology of Disease</i> , 2017 , 105, 117-131	7.5	19
88	Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease. <i>Experimental Neurology</i> , 2017 , 292, 113-124	5.7	5
87	Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease. <i>Experimental Neurology</i> , 2017 , 298, 137-147	5.7	40
86	Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. <i>Scientific Reports</i> , 2017 , 7, 16005	4.9	15
85	CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors. <i>Journal of Neuroscience</i> , 2017 , 37, 11930-11946	6.6	9
84	Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy. <i>Journal of Clinical Investigation</i> , 2017 , 127, 720-734	15.9	75
83	Etiology and Pathogenesis of Parkinson's Disease 2017 , 95-101		3
82	Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model. <i>Neurobiology of Disease</i> , 2016 , 96, 31-37	7.5	10
81	Signaling Mechanisms in l-DOPA-Induced Dyskinesia. <i>Innovations in Cognitive Neuroscience</i> , 2016 , 155-185		
80	Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion. <i>Neurobiology of Disease</i> , 2016 , 94, 213-25	7.5	17
79	Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1423-8	11.5	13
78	Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists. <i>Neurobiology of Disease</i> , 2016 , 96, 156-170	7.5	36
77	On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats. <i>Movement Disorders</i> , 2016 , 31, 149	7	2
76	A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine. <i>Molecular Neurobiology</i> , 2015 , 52, 1152-1164	6.2	13
75	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. <i>Progress in Neurobiology</i> , 2015 , 132, 96-168	10.9	282
74	Rodent Models of Treatment-Related Complications in Parkinson Disease 2015 , 373-386		
73	Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. <i>Neuropharmacology</i> , 2015 , 95, 121-9	5.5	38

72	Increased CSF biomarkers of angiogenesis in Parkinson disease. <i>Neurology</i> , 2015 , 85, 1834-42	6.5	75
71	Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached?. <i>Neurobiology of Disease</i> , 2015 , 82, 561-573	7.5	17
70	M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. <i>Neuron</i> , 2015 , 88, 762-73	13.9	129
69	Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia. <i>Movement Disorders</i> , 2015 , 30, 484-93	7	38
68	Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia. <i>Neuropharmacology</i> , 2015 , 93, 52-67	5.5	55
67	Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. <i>Brain</i> , 2014 , 137, 1998-2014	11.2	139
66	Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. <i>Nature Communications</i> , 2014 , 5, 5316	17.4	181
65	Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse. <i>Parkinsonism and Related Disorders</i> , 2014 , 20 Suppl 1, S20-2	3.6	20
64	Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease. <i>Biochemical Society Transactions</i> , 2014 , 42, 600-4	5.1	12
63	Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. <i>Journal of Neuroscience</i> , 2014 , 34, 4728-40	6.6	65
62	Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 4578-83	11.5	81
61	Presynaptic Mechanisms of L-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications. <i>Frontiers in Neurology</i> , 2014 , 5, 242	4.1	136
60	Preclinical Models of Levodopa-Induced Dyskinesia 2014 , 335-353		
59	Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E4375-84	11.5	18
58	Modulating mGluR5 and 5-HT1A/1B receptors to treat L-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. <i>Experimental Neurology</i> , 2013 , 250, 116-24	5.7	37
57	Bad news for neuroprotective therapies in PD?. <i>Journal of Parkinson's Disease</i> , 2013 , 3, 271-3	5.3	1
56	In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. <i>Neurobiology of Disease</i> , 2012 , 45, 573-82	7.5	59
55	A model of GDNF gene therapy in mice with 6-Hydroxydopamine lesions: time course of Neurorestorative effects and ERK1/2 activation. <i>Journal of Parkinson's Disease</i> , 2012 , 2, 333-48	5.3	10

54	Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. <i>Progress in Neurobiology</i> , 2012 , 96, 69-86	10.9	137
53	Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. <i>NeuroImage</i> , 2012 , 61, 228-39	7.9	57
52	Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. <i>Journal of Neuroscience</i> , 2012 , 32, 16541-51	6.6	87
51	The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study. <i>PLoS ONE</i> , 2011 , 6, e24679	3.7	40
50	Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2011 , 42, 327-40	7.5	121
49	Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. <i>Brain</i> , 2011 , 134, 2339-57	11.2	96
48	L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. <i>Journal of Neurochemistry</i> , 2010 , 112, 1465-76	6	206
47	Calcium-permeable AMPA receptors are involved in the induction and expression of L-DOPA-induced dyskinesia in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2010 , 114, 499-511	6	77
46	6-OH Dopamine Rat Model 2010 , 3-5		
45	Recent advances in Parkinson's disease: basic research. Preface. <i>Progress in Brain Research</i> , 2010 , 183, ix-x	2.9	2
44	Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. <i>Progress in Brain Research</i> , 2010 , 183, 209-33		163
43	Molecular Mechanisms of L-DOPA-Induced Dyskinesia. <i>Handbook of Behavioral Neuroscience</i> , 2010 , 625-649		
42	Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. <i>Experimental Neurology</i> , 2010 , 225, 408-15	5.7	17
41	Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 21824-9	11.5	126
40	Recent Advances in Parkinson's disease - translational and clinical research. <i>Progress in Brain Research</i> , 2010 , 184, vii-viii	2.9	2
39	A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. <i>Neurobiology of Disease</i> , 2010 , 39, 352-61	7.5	135
38	Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. <i>Annals of Neurology</i> , 2010 , 68, 619-28	9.4	192
37	Tail-pinch Stimulus 2010 , 209-210		

36 Climbing Behavior **2010**, 226-227

35 Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 330, 227-35 4.7 146

34 Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. *Neuropsychopharmacology*, **2009**, 34, 2477-88 8.7 70

33 Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. *Neurobiology of Disease*, **2009**, 35, 42-51 7.5 31

32 Chronic intermittent L-DOPA treatment induces changes in dopamine release. *Journal of Neurochemistry*, **2009**, 108, 998-1008 6 30

31 Antagonizing L-type Ca²⁺ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. *Biological Psychiatry*, **2009**, 65, 518-26 7.9 66

30 Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. *Parkinsonism and Related Disorders*, **2009**, 15 Suppl 3, S59-63 3.6 40

29 Rodent models of treatment-induced motor complications in Parkinson's disease. *Parkinsonism and Related Disorders*, **2009**, 15 Suppl 4, S13-7 3.6 24

28 L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. *Neurobiology of Disease*, **2008**, 29, 327-35 7.5 89

27 Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. *Biological Psychiatry*, **2007**, 62, 800-10 7.9 228

26 Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. *Current Protocols in Neuroscience*, **2007**, Chapter 9, Unit 9.25 2.7 162

25 Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. *Journal of Neurochemistry*, **2007**, 101, 483-97 6 183

24 Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. *Journal of Neurochemistry*, **2007**, 102, 1395-409 6 35

23 Advances in understanding L-DOPA-induced dyskinesia. *Current Opinion in Neurobiology*, **2007**, 17, 665-71.6 86

22 Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. *Trends in Neurosciences*, **2007**, 30, 236-43 13.3 216

21 The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. *Behavioural Brain Research*, **2007**, 177, 150-9 3.4 86

20 Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. *Behavioural Brain Research*, **2007**, 179, 76-89 3.4 184

19 L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. *Parkinsonism and Related Disorders*, **2007**, 13 Suppl 3, S263-7 3.6 39

18	Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. <i>Neurobiology of Disease</i> , 2006 , 21, 657-68	7.5	88
17	Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. <i>Journal of Neuroscience</i> , 2006 , 26, 9448-61	6.6	105
16	On the move to stimulate cell plasticity in the substantia nigra in Parkinson's disease. <i>Experimental Neurology</i> , 2006 , 201, 1-6	5.7	2
15	Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. <i>Brain Research Bulletin</i> , 2006 , 69, 318-26	3.9	114
14	Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. <i>Journal of Neurochemistry</i> , 2006 , 99, 381-92	6	176
13	Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. <i>Brain Research Bulletin</i> , 2005 , 68, 4-15	3.9	63
12	Utility of 6-Hydroxydopamine Lesioned Rats in the Preclinical Screening of Novel Treatments for Parkinson Disease 2005 , 193-208		12
11	Abnormal Ca ²⁺ -calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. <i>Journal of Neuroscience</i> , 2004 , 24, 5283-91	6.6	121
10	Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. <i>Neurobiology of Disease</i> , 2004 , 17, 219-36	7.5	131
9	Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. <i>Nature Neuroscience</i> , 2003 , 6, 501-6	25.5	692
8	Models for human neurological disease: both rats and primates are needed. <i>Nature Reviews Neuroscience</i> , 2002 , 3, 580-580	13.5	
7	Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. <i>European Journal of Neuroscience</i> , 2002 , 15, 120-32	3.5	515
6	Animal models of neurological deficits: how relevant is the rat?. <i>Nature Reviews Neuroscience</i> , 2002 , 3, 574-9	13.5	378
5	L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. <i>Neurobiology of Disease</i> , 2002 , 10, 165-86	7.5	338
4	cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. <i>Journal of Neuroscience</i> , 2001 , 21, 9930-43	6.6	120
3	Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. <i>Brain Research</i> , 1992 , 581, 217-28	3.7	182
2	Striatal c-fos Induction by Cocaine or Apomorphine Occurs Preferentially in Output Neurons Projecting to the Substantia Nigra in the Rat. <i>European Journal of Neuroscience</i> , 1992 , 4, 376-380	3.5	117
1	Host Brain Regulation of Fetal Locus Coeruleus Neurons Grafted to the Hippocampus in 6-Hydroxydopamine-Treated Rats. An Intracerebral Microdialysis Study. <i>European Journal of Neuroscience</i> , 1991 , 3, 905-918	3.5	14

